Tehran University of Medical Sciences

Science Communicator Platform

Share By
Quantitative Psma Pet Biomarkers for Predicting Response to 177Lu-Psma Therapy in Prostate Cancer: A Systematic Review and Meta-Analysis Publisher Pubmed



Kiani I ; Siri M A ; Babaei M ; Aliasghari M M ; Mohammadzadeh S ; Mohammadi S ; Salavati A
Authors

Source: Journal of Nuclear Medicine Published:2026


Abstract

177Lu-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (177Lu-PSMA-617) has emerged as a promising targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). However, response rates to therapy vary among patients. Quantitative PSMA PET biomarkers have been increasingly explored for their prognostic potential in guiding patient selection. This systematic review and meta-analysis aims to evaluate the prognostic value of PSMA PET biomarkers for response to 177Lu-PSMA therapy in patients with mCRPC. Methods: A systematic search was conducted across PubMed, Scopus, Web of Science, and Embase databases to identify studies evaluating quantitative PSMA PET parameters as predictors of response to 177Lu-PSMA therapy. Hazard ratios (HRs) and 95% CIs for quantitative PSMA PET parameters were extracted and synthesized using random-effects meta-analysis. Heterogeneity was assessed using I2 statistics, and publication bias was evaluated via funnel plots and the Egger test. Results: A total of 23 studies met the inclusion criteria. Among PSMA PET parameters, SUVmean, tumor volume (TV), or total lesion (TL) PSMA emerged as significant predictors of overall survival (OS), progression free survival, and prostate-specific antigen response. The pooled HR for SUVmean in predicting OS was 0.93 (95% CI, 0.90–0.96; I2 5 92.8%), whereas TV showed a HR of 1.37 (95% CI, 1.27–1.47; I2 5 4.7%), and the TL had a HR of 1.04 (95% CI, 1.03–1.05; I2 5 16.1%). Additionally, SUVmax and SUVpeak demonstrated limited predictive value. Conclusion: Our findings indicate that SUVmean, TV, and TL derived from PSMA PET imaging could serve as valuable biomarkers for prognosticating response to 177Lu-PSMA therapy in patients with mCRPC. Future studies should aim to integrate PET biomarkers with clinical and biochemical parameters to improve treatment decision-making. COPYRIGHT ß 2026 by the Society of Nuclear Medicine and Molecular Imaging.
Related Docs
View other Related Docs
1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-Psma Pet Derived Parameters on Biochemical Response, Overall Survival, and Psa Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Undergoing [177Lu]Lu-Psma Therapy, Nuklearmedizin - NuclearMedicine (2024)
2. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens, Diagnostics (2024)
3. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (4)
Reza Malekzadeh (4)
Other Related Docs
4. Strong Inorganic Acid Mists and Respiratory Tract Cancers: A Meta-Analysis, Occupational Medicine (2024)
5. Breast Cancer Risk Factors in Iranian Women: A Systematic Review and Meta-Analysis of Matched Case–Control Studies, European Journal of Medical Research (2022)
6. Allium Vegetables Intake and the Risk of Gastric Cancer in the Stomach Cancer Pooling (Stop) Project, British Journal of Cancer (2022)
7. Per-And Poly-Fluoroalkyl Substances (Pfas) Exposure and Risk of Kidney, Liver, and Testicular Cancers: A Systematic Review and Meta-Analysis, Medicina del Lavoro (2023)
8. Occupational Exposure to Diesel Exhaust and Head and Neck Cancer: A Systematic Review and Meta-Analysis of Cohort Studies, European Journal of Cancer Prevention (2024)
9. Inverse Association Between Dietary Iron Intake and Gastric Cancer: A Pooled Analysis of Case‐Control Studies of the Stop Consortium, Nutrients (2022)
10. Predictive and Prognostic Potential of Pretreatment 68Ga-Psma Pet Tumor Heterogeneity Index in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With 177Lu-Psma, Frontiers in Oncology (2022)
11. Efficacy and Safety of Lutetium-177 (177Lu)-Psma-617 in Metastatic Castration-Resistant Prostate Cancer Patients With Superscan Pattern: A Retrospective Cohort Study, Annals of Nuclear Medicine (2025)
12. Targeted Radioligand Therapy: Physics and Biology, Internal Dosimetry and Other Practical Aspects During 177Lu/225Ac Treatment in Neuroendocrine Tumors and Metastatic Prostate Cancer, Theranostics (2025)
13. The Relation Between Obesity and Breast Cancer Risk in Women by Considering Menstruation Status and Geographical Variations: A Systematic Review and Meta-Analysis, BMC Women's Health (2023)
14. The Association Between Dietary Fiber Intake and Gastric Cancer: A Pooled Analysis of 11 Case–Control Studies, European Journal of Nutrition (2024)
15. Synthesis, Radiolabeling, and Biodistribution Evaluation of Novel Hyperbranched Polyglycerols-Based Radiotracers for Targeting Psma in Prostate Cancer, Iranian Journal of Basic Medical Sciences (2026)
16. Lung Cancer Risk Prediction Models for Asian Ever-Smokers, Journal of Thoracic Oncology (2024)
17. The Effects of Omega-3 Fatty Acids Supplementation on Inflammatory Factors in Cancer Patients: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials, Nutrition and Cancer (2024)
18. Factors Predicting the Early Biochemical Response to [177Lu]Lu-Psma Therapy in Patients With Metastatic Castration Resistant Prostate Cancer, Iranian Journal of Nuclear Medicine (2022)